002940 昂利康
交易中 03-25 14:28:24
资讯
新帖
简况
3月23日昂利康跌5.62%，华泰柏瑞恒泽混合A基金重仓该股
证券之星 · 03-23 16:56
3月23日昂利康跌5.62%，华泰柏瑞恒泽混合A基金重仓该股
3月20日昂利康创60日新低，华泰柏瑞恒泽混合A基金重仓该股
证券之星 · 03-20
3月20日昂利康创60日新低，华泰柏瑞恒泽混合A基金重仓该股
昂利康（002940）披露调整2025年度向特定对象发行A股股票方案公告，3月19日股价下跌2.29%
证券之星 · 03-19
昂利康（002940）披露调整2025年度向特定对象发行A股股票方案公告，3月19日股价下跌2.29%
昂利康(002940.SZ)取得头孢克肟颗粒药品注册证书
智通财经 · 03-16
昂利康(002940.SZ)取得头孢克肟颗粒药品注册证书
昂利康(002940.SZ)收到碳酸司维拉姆片药品注册证
智通财经 · 03-06
昂利康(002940.SZ)收到碳酸司维拉姆片药品注册证
昂利康(002940.SZ)取得腺苷钴胺胶囊药品注册证
智通财经 · 03-03
昂利康(002940.SZ)取得腺苷钴胺胶囊药品注册证
昂利康（002940）披露获得药品补充申请批准通知书的公告，2月25日股价上涨0.87%
证券之星 · 02-25
昂利康（002940）披露获得药品补充申请批准通知书的公告，2月25日股价上涨0.87%
昂利康最新公告：子公司获得吸入用七氟烷（宠物用）兽药产品批准文号批件
证券之星 · 02-25
昂利康最新公告：子公司获得吸入用七氟烷（宠物用）兽药产品批准文号批件
昂利康最新公告：公司通过多潘立酮片仿制药质量和疗效一致性评价
证券之星 · 02-25
昂利康最新公告：公司通过多潘立酮片仿制药质量和疗效一致性评价
昂利康最新公告：公司产品拟中选国家药品接续采购
证券之星 · 02-11
昂利康最新公告：公司产品拟中选国家药品接续采购
昂利康（002940）披露2025年度业绩预告，1月29日股价下跌1.27%
证券之星 · 01-29
昂利康（002940）披露2025年度业绩预告，1月29日股价下跌1.27%
昂利康（002940）披露子公司通过高新技术企业重新认定，1月15日股价下跌2.22%
证券之星 · 01-15
昂利康（002940）披露子公司通过高新技术企业重新认定，1月15日股价下跌2.22%
异动快报：昂利康（002940）1月12日14点20分触及涨停板
证券之星 · 01-12
异动快报：昂利康（002940）1月12日14点20分触及涨停板
每周股票复盘：昂利康（002940）募投项目延期至2026年6月
证券之星 · 01-03
每周股票复盘：昂利康（002940）募投项目延期至2026年6月
昂利康（002940）披露2025年第三次临时股东会决议公告，12月16日股价上涨1.37%
证券之星 · 2025-12-16
昂利康（002940）披露2025年第三次临时股东会决议公告，12月16日股价上涨1.37%
昂利康：将研发作为核心发展动力
证券之星 · 2025-12-16
昂利康：将研发作为核心发展动力
12月15日昂利康创60日新低，富国天盛灵活配置基金基金重仓该股
证券之星 · 2025-12-15
12月15日昂利康创60日新低，富国天盛灵活配置基金基金重仓该股
昂利康（002940）披露获得药品注册证书及药品补充申请批准通知书，12月12日股价下跌6.63%
证券之星 · 2025-12-12
昂利康（002940）披露获得药品注册证书及药品补充申请批准通知书，12月12日股价下跌6.63%
12月12日昂利康跌6.63%，富国天盛灵活配置基金基金重仓该股
证券之星 · 2025-12-12
12月12日昂利康跌6.63%，富国天盛灵活配置基金基金重仓该股
昂利康11.6亿定增押注创新药，毛利率持续滑坡下寻求转型突围
证券之星 · 2025-12-11
昂利康11.6亿定增押注创新药，毛利率持续滑坡下寻求转型突围
加载更多
公司概况
公司名称：
浙江昂利康制药股份有限公司
所属行业：
医药制造业
上市日期：
2018-10-23
主营业务：
浙江昂利康制药股份有限公司的主营业务是从事化学原料药及制剂的研发、生产和销售。公司的主要产品是化学原料药及制剂。
发行价格：
23.07
{"stockData":{"symbol":"002940","market":"SZ","secType":"STK","nameCN":"昂利康","latestPrice":29.06,"timestamp":1774420104000,"preClose":28.8,"halted":0,"volume":2996951,"delay":0,"changeRate":0.009,"floatShares":185000000,"shares":202000000,"eps":0.5359,"marketStatus":"交易中","change":0.26,"latestTime":"03-25 14:28:24","open":28.81,"high":29.29,"low":28.61,"amount":87215100,"amplitude":0.0236,"askPrice":29.09,"askSize":34,"bidPrice":29.06,"bidSize":15,"shortable":0,"etf":0,"ttmEps":0.5359,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774422000000},"marketStatusCode":2,"adr":0,"adjPreClose":28.8,"symbolType":"stock","openAndCloseTimeList":[[1774402200000,1774409400000],[1774414800000,1774422000000]],"highLimit":31.68,"lowLimit":25.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201728186,"isCdr":false,"pbRate":3.65,"roa":"--","peRate":54.226535,"roe":"4.99%","epsLYR":0.4,"committee":-0.111111,"marketValue":5862000000,"turnoverRate":0.0162,"status":0,"floatMarketCap":5384000000},"requestUrl":"/m/hq/s/002940","defaultTab":"news","newsList":[{"id":"2621779858","title":"3月23日昂利康跌5.62%，华泰柏瑞恒泽混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621779858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621779858?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:56","pubTimestamp":1774256176,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日昂利康跌5.62%创60日新低，收盘报27.38元，换手率2.72%，成交量5.03万手，成交额1.41亿元。重仓昂利康的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为华泰柏瑞基金的华泰柏瑞恒泽混合A。华泰柏瑞恒泽混合A目前规模为0.41亿元，最新净值1.1176，较上一交易日下跌0.04%，近一年上涨3.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2620861347","title":"3月20日昂利康创60日新低，华泰柏瑞恒泽混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620861347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620861347?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:24","pubTimestamp":1773995044,"startTime":"0","endTime":"0","summary":"证券之星消息，3月20日昂利康创60日新低，收盘报29.01元，当日跌2.68%，换手率1.63%，成交量3.03万手，成交额8926.51万元。重仓昂利康的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为华泰柏瑞基金的华泰柏瑞恒泽混合A。华泰柏瑞恒泽混合A目前规模为0.41亿元，最新净值1.118，较上一交易日下跌0.09%，近一年上涨3.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000027709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2620221822","title":"昂利康（002940）披露调整2025年度向特定对象发行A股股票方案公告，3月19日股价下跌2.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221822","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620221822?lang=zh_cn&edition=full","pubTime":"2026-03-19 22:31","pubTimestamp":1773930671,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘，昂利康报收于29.81元，较前一交易日下跌2.29%，最新总市值为60.14亿元。该股当日开盘30.2元，最高30.43元，最低29.65元，成交额达9091.43万元，换手率为1.64%。公告显示，公司于2026年3月18日召开第四届董事会第十七次会议，审议通过了关于调整公司2025年度向特定对象发行A股股票方案的议案。因ALK-N001项目临床进展及ALK-N002项目交易对方内部审批进度原因，董事会同意将募集资金总额由116,000.00万元调整为112,000.00万元，全部用于创新药研发项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900039846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","159982","399300","BK0239"],"gpt_icon":0},{"id":"2619245934","title":"昂利康(002940.SZ)取得头孢克肟颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619245934","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619245934?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:37","pubTimestamp":1773653837,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康(002940.SZ)公告，公司收到国家药品监督管理局签发的头孢克肟颗粒《药品注册证书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2617201683","title":"昂利康(002940.SZ)收到碳酸司维拉姆片药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2617201683","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617201683?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:39","pubTimestamp":1772786355,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康(002940.SZ)公告，公司收到国家药品监督管理局签发的碳酸司维拉姆片《药品注册证书》。碳酸司维拉姆片用于控制正在接受透析治疗的慢性肾脏病(CKD)成人患者的高磷血症;用于控制血清磷≥1.78mmol/L但并未进行透析的慢性肾脏病成人患者的高磷血症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昂利康(002940.SZ)收到碳酸司维拉姆片药品注册证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2616484023","title":"昂利康(002940.SZ)取得腺苷钴胺胶囊药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616484023","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616484023?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:37","pubTimestamp":1772530631,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康(002940.SZ)公告，公司收到国家药品监督管理局签发的腺苷钴胺胶囊《药品注册证书》。腺苷钴胺胶囊适用于巨幼红细胞性贫血，营养不良性贫血、妊娠期贫血、多发性神经炎、神经根炎、三叉神经痛、坐骨神经痛、神经麻痹;也可用于营养性疾患以及放射线和药物引起的白细胞减少症的辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昂利康(002940.SZ)取得腺苷钴胺胶囊药品注册证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2614035932","title":"昂利康（002940）披露获得药品补充申请批准通知书的公告，2月25日股价上涨0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614035932","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614035932?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:34","pubTimestamp":1772030057,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，昂利康报收于32.46元，较前一交易日上涨0.87%，最新总市值为65.48亿元。该股当日开盘32.16元，最高32.54元，最低32.08元，成交额达1.06亿元，换手率为1.77%。近日，浙江昂利康制药股份有限公司收到国家药品监督管理局签发的多潘立酮片《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价，同时批准处方、生产工艺、批量及注册标准变更。多潘立酮片适用于消化不良、腹胀、嗳气、恶心、呕吐、腹部胀痛等症状。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2614333083","title":"昂利康最新公告：子公司获得吸入用七氟烷（宠物用）兽药产品批准文号批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2614333083","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614333083?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:41","pubTimestamp":1772016093,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称，公司子公司浙江昂利康动保科技有限公司收到农业农村部核准签发的“吸入用七氟烷（宠物用）”兽药产品批准文号批件。该兽药具备生产上市销售条件，可进一步丰富公司产品品类，对推动宠物用药战略布局、促进公司发展具有积极意义。但具体销售情况存在较大不确定性，投资者需审慎决策，注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500031928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2614608338","title":"昂利康最新公告：公司通过多潘立酮片仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2614608338","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614608338?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:41","pubTimestamp":1772016076,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称，公司收到国家药品监督管理局签发的多潘立酮片《药品补充申请批准通知书》，通过仿制药质量和疗效一致性评价。该药品用于消化不良、腹胀、嗳气、恶心、呕吐、腹部胀痛。通过一致性评价将提升公司市场竞争力，但销售情况受政策、市场环境等因素影响，存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500031927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2610763980","title":"昂利康最新公告：公司产品拟中选国家药品接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610763980","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610763980?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:31","pubTimestamp":1770802308,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称，公司参与了国家组织集采第1-8批协议期满品种接续采购的申报，部分产品拟中选本次接续采购。拟中选产品包括苯磺酸左氨氯地平片、苯磺酸氨氯地平片、铝碳酸镁咀嚼片等。2024年度合计销售额为21,420万元，占公司2024年度营业收入比例为13.93%。若后续签订采购合同并实施，将有利于扩大产品销售规模，提高市场占有率，对公司未来经营业绩产生积极影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100027884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2607003505","title":"昂利康（002940）披露2025年度业绩预告，1月29日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607003505","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607003505?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:40","pubTimestamp":1769697630,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，昂利康报收于31.99元，较前一交易日下跌1.27%，最新总市值为64.53亿元。该股当日开盘32.17元，最高32.56元，最低31.71元，成交额达1.41亿元，换手率为2.37%。近日，浙江昂利康制药股份有限公司发布2025年度业绩预告。公告显示，公司预计2025年度归属于上市公司股东的净利润为11,000万元至13,800万元，同比增长36.93%至71.78%；扣除非经常性损益后的净利润为7,100万元至9,900万元，同比增长46.68%至104.52%。该业绩预告未经审计，最终数据以2025年年度报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900043828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2603857739","title":"昂利康（002940）披露子公司通过高新技术企业重新认定，1月15日股价下跌2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603857739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603857739?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:23","pubTimestamp":1768486991,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，昂利康报收于35.67元，较前一交易日下跌2.22%，最新总市值为71.96亿元。公司近日发布公告称，其控股子公司浙江昂利泰制药有限公司通过了高新技术企业重新认定，并获得编号为GR202533009362的《高新技术企业证书》，发证日期为2025年12月19日，有效期三年。此次为有效期满后的重新认定，昂利泰将继续享受国家高新技术企业税收优惠政策，2025年至2027年按15%的税率缴纳企业所得税。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500040886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2602595029","title":"异动快报：昂利康（002940）1月12日14点20分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2602595029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602595029?lang=zh_cn&edition=full","pubTime":"2026-01-12 14:25","pubTimestamp":1768199123,"startTime":"0","endTime":"0","summary":"证券之星1月12日盘中消息，14点20分昂利康触及涨停板。其所属行业化学制药目前上涨。领涨股为向日葵。该股为宠物经济，合成生物，化学原料药概念热股，当日宠物经济概念上涨1.54%，合成生物概念上涨1.17%，化学原料药概念上涨0.67%。1月9日的资金流向数据方面，主力资金净流出127.6万元，占总成交额0.37%，游资资金净流出256.34万元，占总成交额0.74%，散户资金净流入383.94万元，占总成交额1.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200013979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2600062294","title":"每周股票复盘：昂利康（002940）募投项目延期至2026年6月","url":"https://stock-news.laohu8.com/highlight/detail?id=2600062294","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600062294?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:18","pubTimestamp":1767377894,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，昂利康报收于33.52元，较上周的33.82元下跌0.89%。本周，昂利康12月29日盘中最高价报34.0元。关于募集资金投资项目之杭州药物研发平台项目延期的公告浙江昂利康制药股份有限公司于2025年12月30日召开董事会，审议通过杭州药物研发平台项目延期议案，将项目达到预定可使用状态日期由2025年12月延至2026年6月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2591980975","title":"昂利康（002940）披露2025年第三次临时股东会决议公告，12月16日股价上涨1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591980975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591980975?lang=zh_cn&edition=full","pubTime":"2025-12-16 22:11","pubTimestamp":1765894302,"startTime":"0","endTime":"0","summary":"截至2025年12月16日收盘，昂利康报收于33.41元，较前一交易日上涨1.37%，最新总市值为67.4亿元。该股当日开盘32.78元，最高33.96元，最低32.25元，成交额达3.55亿元，换手率为5.8%。近日，浙江昂利康制药股份有限公司召开2025年第三次临时股东会，会议审议通过了关于公司符合向特定对象发行A股股票条件、2025年度向特定对象发行A股股票方案、发行预案、募集资金使用可行性分析、前次募集资金使用情况、股东回报规划等九项议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600040533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2591672245","title":"昂利康：将研发作为核心发展动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2591672245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591672245?lang=zh_cn&edition=full","pubTime":"2025-12-16 11:37","pubTimestamp":1765856220,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康(002940)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司的核心竞争力是什么？昂利康回复：您好，目前国内医药生产企业众多，竞争较为激烈，公司始终坚持将研发作为企业的核心发展动力，注重业内合作，立足于开发具有临床价值的优质产品。详情可参考公司各年年度报告“第三节 管理层讨论与分析”，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600015370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2591615658","title":"12月15日昂利康创60日新低，富国天盛灵活配置基金基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591615658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591615658?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:37","pubTimestamp":1765784256,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日昂利康创60日新低，收盘报32.96元，当日跌3.68%，换手率5.06%，成交量9.38万手，成交额3.14亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为富国基金的富国天盛灵活配置基金。富国天盛灵活配置基金目前规模为6.7亿元，最新净值1.322，较上一交易日下跌0.9%，近一年上涨34.62%。该公募基金现任基金经理为肖威兵。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500013035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2590504230","title":"昂利康（002940）披露获得药品注册证书及药品补充申请批准通知书，12月12日股价下跌6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590504230?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:05","pubTimestamp":1765548345,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，昂利康报收于34.22元，较前一交易日下跌6.63%，最新总市值为69.03亿元。公司近日发布公告称，浙江昂利康制药股份有限公司近日收到国家药监局签发的双氯芬酸钠肠溶片《药品注册证书》和沙库巴曲缬沙坦钠片《药品补充申请批准通知书》。双氯芬酸钠肠溶片获批规格为25mg，注册分类为化学药品4类，视同通过一致性评价。沙库巴曲缬沙坦钠片获批增加100mg规格，此前已有200mg规格获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200040638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2590750745","title":"12月12日昂利康跌6.63%，富国天盛灵活配置基金基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590750745","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590750745?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:39","pubTimestamp":1765525180,"startTime":"0","endTime":"0","summary":"证券之星消息，12月12日昂利康跌6.63%创60日新低，收盘报34.22元，换手率8.42%，成交量15.6万手，成交额5.38亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为富国基金的富国天盛灵活配置基金。富国天盛灵活配置基金目前规模为6.7亿元，最新净值1.334，较上一交易日上涨0.0%，近一年上涨36.82%。该公募基金现任基金经理为肖威兵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200018748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2590568565","title":"昂利康11.6亿定增押注创新药，毛利率持续滑坡下寻求转型突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2590568565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590568565?lang=zh_cn&edition=full","pubTime":"2025-12-11 10:14","pubTimestamp":1765419273,"startTime":"0","endTime":"0","summary":"未来，昂利康能否凭借差异化优势在创新药中成功突围，将直接决定其长远成长空间。战略转向落子创新药，11.6亿元押注肿瘤领域核心管线根据昂利康披露的定增预案，此次募集的11.6亿元将全额投入创新药研发及产业相关项目，精准聚焦肿瘤疾病领域的创新突破。此次将全部募资集中投向创新药领域，清晰彰显了昂利康战略重心的彻底转移。回顾发展历程，昂利康的创新药转型并非一蹴而就。因此，昂利康这场规模达11.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025121100009629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1574","159992","06978","002940"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774420107347,"stockEarnings":[{"period":"1week","weight":-0.0448},{"period":"1month","weight":-0.0994},{"period":"3month","weight":-0.1497},{"period":"6month","weight":-0.2572},{"period":"1year","weight":1.1886},{"period":"ytd","weight":-0.1408}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.0492},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0073},{"period":"1year","weight":0.1517},{"period":"ytd","weight":-0.0221}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江昂利康制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"28533人(较上一季度增加54.58%)","perCapita":"6493股","listingDate":"2018-10-23","address":"浙江省绍兴市嵊州市嵊州大道北1000号","registeredCapital":"20172万元","survey":" 浙江昂利康制药股份有限公司的主营业务是从事化学原料药及制剂的研发、生产和销售。公司的主要产品是化学原料药及制剂。","listedPrice":23.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昂利康,002940,昂利康股票,昂利康股票老虎,昂利康股票老虎国际,昂利康行情,昂利康股票行情,昂利康股价,昂利康股市,昂利康股票价格,昂利康股票交易,昂利康股票购买,昂利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}